Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraveheart Investments Regulatory News (BRH)

  • There is currently no data for BRH

Directorate Change

5 Jun 2008 07:00

RNS Number : 0126W
Braveheart Investment Group plc
05 June 2008
 



For release 07.00, 5 June 2008

Braveheart Investment Group plc

("Braveheart" or the "Group")

DIRECTORATE CHANGE

Appointment of Jeremy Delmar-Morgan to the Board

Braveheart (AIM: BRH), the technology commercialisation and investment management company, announces that Jeremy Delmar-Morgan has been appointed as a Non-Executive Director to the Board with effect from 3 June 2008. 

Jeremy Delmar-Morgan joins Braveheart with a strong background in the financial services and investment arena. He has spent much of his recent career at Teather & Greenwood where he was a senior partner from 1985 until 1997. When Teather & Greenwood became a public company in 1998 Jeremy was promoted to Chief Executive before moving on to the role of Chairman of the Board in 2000. He retired as Chairman in 2004. 

Jeremy has a MA from Magdalene College, Cambridge and is a member of the Securities Institute. He started his career at Hoblyn Dix & Maurice and as a Director of Vickers Da Costa. Currently Jeremy is Non-Executive Chairman of Hichens Harrison, London's longest established stockbroker and a Non-Executive Director of Sefton Resources Inc. He is also a director of a number of private companies and entities including: the London Symphony Orchestra and Eagle Crown Productions. Details of the other companies are listed below. 

Commenting on the appointment, Geoffrey Thomson, Chief Executive of Braveheart said, "I am very pleased to be welcoming Jeremy to the Board. He has a wealth of City experience which will be of direct benefit to us as we go forward. This is the first appointment we have made outside Scotland and it demonstrates our commitment to expanding our area of operations." 

Jeremy Delmar-Morganadded: "I am delighted to be joining the Board of Braveheart. The Group has an impressive track record and strong relationships with both investors and universities, and uses them to great effect. I am looking forward to working with Geoffrey and the team." 

Additional Disclosures

In the previous five years Jeremy Delmar-Morgan has been a director of the following companies and remains a director:

Hichens, Harrison & Co. plc

Hichens, Harrison (Ventures) Limited

Eagle Crown Productions Limited 

Ex-Services Mental Welfare Society

Jem (Developments) Limited

London Symphony Orchestra Limited 

Sefton Resources Inc.

Seven Hills Venture Partners Limited 

The BrendonCare Foundation 

In the previous five years Jeremy Delmar-Morgan has been a director of the following companies, in relation to which he is no longer a director: 

Apart Residential II plc

Apart Residential Limited 

Camomile Wood Nominees Limited 

CDML Limited 

Eastern Countries Homestart Option plc

Insignia cashbacked III plc

Teather & Greenwood Corporate Finance Limited 

Teather & Greenwood Holdings plc (now changed to Landsbanki Securities (UK) Holdings plc)

Teather & Greenwood Limited

Teather & Greenwood Nominees Limited 

Teawood Nominees Limited

Technical Research Limited 

Save for the information disclosed above, there are no further matters which are required to be disclosed with regard to this appointment under paragraph 2 (g) of the AIM Rules.

For further information please visit www.braveheart-ventures.co.uk or contact:

Braveheart Investment Group

Tavistock Communications (for Braveheart)

Geoffrey Thomson, Chief Executive

Clemmie Carr / Simon Hudson

Tel: 01738 587555

Tel: 020 7920 3150

gthomson@braveheart-ventures.co.uk

carr@tavistock.co.uk 

Notes to Editors

Braveheart

Braveheart Investment Group is a technology commercialisation and investment management company based in PerthScotland. Since its formation in 1997 it has made the transition from start-up angel syndicate to fully listed company. Braveheart's shares listed on AIM in March 2007.

Investments are made in young, emerging, unlisted companies where there is potential for significant growth through successful commercialisation of IP and Braveheart enjoys close relationships with several universities to identify emerging technologies. Investments are predominantly technology-focusedhowever the Group also maintains limited exposure to more traditional businesses.

Braveheart's diverse portfolio currently comprises over 30 companies and it has completed over 70 deals in its ten year historyincluding 6 IPOs, 3 trade sales and 8 write-offs and has an exit IRR of 37%.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUUURPQUPRGQC
Date   Source Headline
10th Oct 20251:20 pmRNSConfirmation of change of name and website
26th Sep 20257:00 amRNSProposed Change of Name
9th Sep 20257:00 amRNSBlock admission six monthly return
2nd Sep 202511:23 amRNSHolding(s) in Company
1st Aug 20253:04 pmRNSResult of AGM
9th Jul 20252:41 pmRNSFinal Results and Notice of AGM
30th May 20255:00 pmRNSTotal Voting Rights
27th May 20253:15 pmRNSHolding(s) in Company
21st May 20257:00 amRNSResult of Broker Option and Total Voting Rights
16th May 20252:08 pmRNSPlacing to raise £135,000
14th May 202511:55 amRNSHolding(s) in Company
18th Mar 202510:30 amRNSSubscription in IQ-AI Ltd Placing
6th Mar 202510:03 amRNSBlock admission six monthly return
3rd Feb 20257:00 amRNSCancellation of options
20th Jan 20255:32 pmRNSDirector/PDMR Shareholding - acquisition of shares
14th Jan 202511:15 amRNSHolding(s) in Company
8th Jan 20254:54 pmRNSChange of Auditor
10th Dec 20241:28 pmRNSDirector/PDMR Shareholding
9th Dec 202412:16 pmRNSDirector/PDMR Shareholding - acquisition of shares
2nd Dec 20244:22 pmRNSHolding(s) in Company
2nd Dec 20249:05 amRNSDirector/PDMR Shareholding
7th Nov 202411:10 amRNSHolding(s) in Company
7th Nov 202411:06 amRNSDirector/PDMR Shareholding - acquisition of shares
15th Oct 202410:28 amRNSHolding(s) in Company
15th Oct 20247:00 amRNSHalf-year Report
11th Oct 202410:00 amRNSInvestment in IQ-AI Limited and RPT
26th Sep 20249:35 amRNSAppointment of representative to Board of Autins
9th Sep 202410:15 amRNSBlock admission six monthly return
4th Sep 20247:00 amRNSHolding(s) in Company
20th Aug 20245:15 pmRNSHolding(s) in Company
7th Aug 20247:00 amRNSHolding(s) in Company
7th Aug 20247:00 amRNSAcquisition of interest in Image Scan Holdings plc
6th Aug 20245:30 pmRNSHolding(s) in Company
1st Aug 20247:00 amRNSInvestment update – Gyrometric
24th Jul 20247:00 amRNSInvestment update - Kirkstall and Paraytec
24th Jul 20247:00 amRNSHolding(s) in Company
18th Jul 20242:23 pmRNSResult of AGM
15th Jul 20244:27 pmRNSGrant of options
26th Jun 20242:03 pmRNSAcquisition of further interest in Autins Group
21st Jun 20247:00 amRNSFinal Results and Notice of AGM
15th May 202411:22 amRNSRevaluation of portfolio assets
29th Apr 20242:07 pmRNSHolding(s) in Company
29th Apr 20241:42 pmRNSBlock admission six monthly return
10th Apr 20247:00 amRNSHolding(s) in Company
27th Mar 202412:03 pmRNSHolding(s) in Company
6th Mar 20247:00 amRNSAcquisition of further interest in Autins Group
4th Mar 202411:48 amRNSInvestment update – Paraytec Limited
4th Mar 20247:00 amRNSCompletion of sale of Phasefocus
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.